Business Wire

Leapmotor's First Mass Production Model With CTC Technology


On February 25, 2022, Leapmotor for the first time announced the highlights of its new model C01. It is an electric mid-to-large-sized sedan developed on its C-Vehicle Platform, and also the first mass production model equipped with CTC battery technology, acceleration to 100 km/h in less than 4 seconds, 5-meter plus length and 700km ultra-long range. It will also further expand the portfolio with a planned launch in Q2 of 2022.

Technological and Natural Aesthetics to Create an Inner "Style"

Leapmotor C01 takes natural aesthetics as the design concept, emphasizing smart mobility experience. The design of C01 is featured with technical elements, offering a comfortable environment while the immersive cabin brings a luxurious experience for young, high-end, urban families.

C01 Key Product Features Unveiled

Because of Leapmotor's full-suite of R&D capabilities, the C01 offers compelling features – CTC technology, acceleration, vehicle length and NEDC range. It is set to become a popular product on the EV market.

NO.1 – Leapmotor’s First Mass Production Model with CTC Technology

CTC (Cell-To-Chassis) is a cutting-edge technology that integrates battery into the chassis, leading to greater shock resistance and improved strength of the vehicle. The C01 offers better handling performance, range and collision safety thanks to the CTC Technology.

0-100 km/h Acceleration in less than 4 seconds — Fastest acceleration among electric sedans within the same class in China, supercar-level performance

Leapmotor C01 has one of the fastest acceleration among electric sedans within the same class in China. It is equipped with "Higher Dimension" intelligent power system, using variable-structured oil-cooled electric drive with up to 1 million kilometers lifespan and the world's top NVH performance and power efficiency, meeting the demand for long range and high performance of EVs. In addition, flush door handle, sportback design, 0.226 ultra-low drag coefficient and 5% reduced vehicle weight will offer better performance.

Vehicle Length of over 5 Meter — Mid-to-large-sized sedan

As a mid-to-large sedan, Leapmotor C01 has a 5-meter plus length, wider rear legroom and large trunk space, offering exceptional comfort.

700km Ultra-long NEDC Range — Meeting long-distance travel needs

The C01 is equipped with a 90kWh ultra-large battery, capable of 700km ultra-long NEDC range, meeting consumer needs for long-distance travel. With penetrated large module scheme and intelligent battery management system can improve battery life, range and overall safety.

Full-suite of R&D capabilities Empowering Innovation

Leapmotor has been committed to growing its portfolio of R&D capabilities, obtaining and declaring 1,474 patents, 939 of which have been approved, and more than 40% of which are innovation patents.

Leapmotor increased its product line in 2021 by releasing the C11 as a mid-sized smart electric SUV, entering the RMB 150,000-200,000 SUV sector that has long been dominated by automakers.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Tammy Hu
Phone number: +86-15724268142

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure™) Improves Muscle Strength and Exercise Performance in Middle Aged Adults17.5.2022 18:04:00 EEST | Press release

Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise. This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondri

RMS Launches New Cloud-Based Application UnderwriteIQ17.5.2022 17:47:00 EEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, announces it will be launching a new application, UnderwriteIQ™, hosted on the cloud-based RMS Intelligent Risk Platform™. UnderwriteIQ enables underwriters to have greater control of risks by bringing hazard, exposure, and loss data together in the underwriting process at the point of decision – all based on RMS model science and data. The new application will allow underwriters to price with confidence, enable consistent risk decisions, and improve operational efficiency. The application is hosted on the modular and unified RMS Intelligent Risk Platform (IRP). The platform provides proprietary and tertiary data analytics to rapidly generate high-resolution risk insights via applications that meet underwriting and portfolio management needs. Moe Khosravy, Executive Vice President, Software and Platform, RMS, said: “The growth in adoption of the RMS Intelligent Risk Platform has been phenomenal. A

GC Aesthetics® Announces the Launch of FixNip™: a Total Game-Changer in Breast Reconstruction17.5.2022 17:15:00 EEST | Press release

GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Healthcare Aesthetic Solutions, announced the launch of an Innovative Nipple Areola Complex (NAC) Reconstruction Implant : FixNip™ NRI. This unrivalled medical device is the answer to a well-known clinical need of thousands of women around the world. Until now, a variety of surgical techniques are used to try to reconstruct the nipple areola complex with none providing a long term aesthetic solution. GC Aesthetics® in an exclusive partnership agreement with FixNip LTD is proud of launching FixNip NRI in main European Territories, while the roll-out to Latin America, Central Europe and Asia will be announced later this year. "We are committed to deliver safe options that establish a newer, higher, and more beneficial standard of care for women who seek to total breast reconstruction. Such technology breakthrough will complete our range of solutions dedicated to women aesthetic healthcare. FixNip by GC Aest

Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse17.5.2022 17:00:00 EEST | Press release

Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment. This press release features multimedia. View the full release here: LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire) “We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster

Regulatory Framework for E-cigarettes Essential in Moroccan and Algerian Markets as Prevalence of Smoking Expected to Rise Notably By 202517.5.2022 16:26:00 EEST | Press release

RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks. According to data compiled by website (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco. In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. [1]. While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per [2]. In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom